Arrowhead Pharmaceuticals (ARWR) to Release Quarterly Earnings on Monday

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) is expected to post its quarterly earnings results after the market closes on Monday, February 10th. Analysts expect Arrowhead Pharmaceuticals to post earnings of ($0.42) per share and revenue of $19.05 million for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.

Arrowhead Pharmaceuticals Stock Performance

Shares of Arrowhead Pharmaceuticals stock traded down $0.22 during midday trading on Tuesday, hitting $20.03. The company had a trading volume of 1,446,006 shares, compared to its average volume of 2,943,718. Arrowhead Pharmaceuticals has a 12-month low of $17.05 and a 12-month high of $36.72. The company has a fifty day simple moving average of $20.79 and a 200 day simple moving average of $21.87. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 2.06. The stock has a market cap of $2.49 billion, a price-to-earnings ratio of -3.99 and a beta of 0.97.

Analysts Set New Price Targets

ARWR has been the subject of a number of research reports. StockNews.com raised Arrowhead Pharmaceuticals to a "sell" rating in a research report on Friday, December 20th. HC Wainwright reiterated a "buy" rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Thursday, January 23rd. Citigroup cut their price objective on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a "neutral" rating for the company in a report on Wednesday, November 27th. Sanford C. Bernstein cut their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a "market perform" rating for the company in a report on Friday, November 29th. Finally, Chardan Capital restated a "buy" rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Thursday, December 12th. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, Arrowhead Pharmaceuticals currently has an average rating of "Hold" and a consensus price target of $43.33.

Insider Transactions at Arrowhead Pharmaceuticals

In related news, Director Adeoye Y. Olukotun sold 2,850 shares of the company's stock in a transaction that occurred on Friday, December 27th. The shares were sold at an average price of $20.00, for a total transaction of $57,000.00. Following the sale, the director now directly owns 36,740 shares of the company's stock, valued at $734,800. This represents a 7.20 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director William D. Waddill sold 3,748 shares of the business's stock in a transaction on Monday, December 16th. The stock was sold at an average price of $21.90, for a total value of $82,081.20. Following the transaction, the director now directly owns 44,125 shares of the company's stock, valued at $966,337.50. The trade was a 7.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 147,432 shares of company stock worth $2,957,986 in the last 90 days. Insiders own 4.50% of the company's stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.